» Articles » PMID: 34093104

Interactions Between Tumor Biology and Targeted Nanoplatforms for Imaging Applications

Overview
Journal Adv Funct Mater
Date 2021 Jun 7
PMID 34093104
Citations 8
Authors
Affiliations
Soon will be listed here.
Abstract

Although considerable efforts have been conducted to diagnose, improve, and treat cancer in the past few decades, existing therapeutic options are insufficient, as mortality and morbidity rates remain high. Perhaps the best hope for substantial improvement lies in early detection. Recent advances in nanotechnology are expected to increase the current understanding of tumor biology, and will allow nanomaterials to be used for targeting and imaging both in vitro and in vivo experimental models. Owing to their intrinsic physicochemical characteristics, nanostructures (NSs) are valuable tools that have received much attention in nanoimaging. Consequently, rationally designed NSs have been successfully employed in cancer imaging for targeting cancer-specific or cancer-associated molecules and pathways. This review categorizes imaging and targeting approaches according to cancer type, and also highlights some new safe approaches involving membrane-coated nanoparticles, tumor cell-derived extracellular vesicles, circulating tumor cells, cell-free DNAs, and cancer stem cells in the hope of developing more precise targeting and multifunctional nanotechnology-based imaging probes in the future.

Citing Articles

Herbal Theranostics: Controlled, Targeted Delivery and Imaging of Herbal Molecules.

Setia A, Vallamkonda B, Challa R, Mehata A, Badgujar P, Muthu M Nanotheranostics. 2024; 8(3):344-379.

PMID: 38577318 PMC: 10988210. DOI: 10.7150/ntno.94987.


An Overview of Current Progress and Challenges in Brain Cancer Therapy Using Advanced Nanoparticles.

Chauhan M, Singh R, Sonali , Zia G, Shekhar S, Yadav B Recent Pat Nanotechnol. 2023; 18(3):295-304.

PMID: 37904557 DOI: 10.2174/1872210517666230815105031.


Immunotherapies targeting tumor vasculature: challenges and opportunities.

Dianat-Moghadam H, Nedaeinia R, Keshavarz M, Azizi M, Kazemi M, Salehi R Front Immunol. 2023; 14:1226360.

PMID: 37727791 PMC: 10506263. DOI: 10.3389/fimmu.2023.1226360.


The role of lactate metabolism-related LncRNAs in the prognosis, mutation, and tumor microenvironment of papillary thyroid cancer.

Xia M, Wang S, Wang L, Mei Y, Tu Y, Gao L Front Endocrinol (Lausanne). 2023; 14:1062317.

PMID: 37025405 PMC: 10070953. DOI: 10.3389/fendo.2023.1062317.


Nanoengineering facilitating the target mission: targeted extracellular vesicles delivery systems design.

Song H, Chen X, Hao Y, Wang J, Xie Q, Wang X J Nanobiotechnology. 2022; 20(1):431.

PMID: 36175866 PMC: 9524104. DOI: 10.1186/s12951-022-01638-9.


References
1.
Meng Q, Rao L, Zan M, Chen M, Yu G, Wei X . Macrophage membrane-coated iron oxide nanoparticles for enhanced photothermal tumor therapy. Nanotechnology. 2018; 29(13):134004. DOI: 10.1088/1361-6528/aaa7c7. View

2.
Benezra M, Penate-Medina O, Zanzonico P, Schaer D, Ow H, Burns A . Multimodal silica nanoparticles are effective cancer-targeted probes in a model of human melanoma. J Clin Invest. 2011; 121(7):2768-80. PMC: 3223837. DOI: 10.1172/JCI45600. View

3.
Shtivelman E, Hensing T, Simon G, Dennis P, Otterson G, Bueno R . Molecular pathways and therapeutic targets in lung cancer. Oncotarget. 2014; 5(6):1392-433. PMC: 4039220. DOI: 10.18632/oncotarget.1891. View

4.
Lutz A, Bachawal S, Drescher C, Pysz M, Willmann J, Gambhir S . Ultrasound molecular imaging in a human CD276 expression-modulated murine ovarian cancer model. Clin Cancer Res. 2014; 20(5):1313-22. PMC: 3965293. DOI: 10.1158/1078-0432.CCR-13-1642. View

5.
Berghoff A, Kovanda A, Melchardt T, Bartsch R, Hainfellner J, Sipos B . αvβ3, αvβ5 and αvβ6 integrins in brain metastases of lung cancer. Clin Exp Metastasis. 2014; 31(7):841-51. DOI: 10.1007/s10585-014-9675-0. View